Type 1 diabetes mellitus in pediatric age group: A rising endemic

Rachna Pasi¹, Kumar Satish Ravi²

¹Department of Pediatrics, All India Institute of Medical Sciences Mangalagiri, Andhra Pradesh, ²Department of Anatomy, All India Institute of Medical Sciences Rishikesh, Uttarakhand, India

ABSTRACT

Type 1 Diabetes Mellitus is the most common endocrinological abnormality found in children. The incidence of T1DM has steadily increased in nearly all parts of the world. Both genetic susceptibility and environmental factors contribute to the pathogenesis. It is caused due to either decreased or absent insulin production in the body due to multiple etiologies. We have done a literature review of type 1 DM in children and a clinical audit of point prevalence of type 1 DM cases & its clinical correlates of patients presenting at the tertiary level hospital, AIIMS Rishikesh, over two years six months period (April 2015 to September 2017). We found the prevalence of diabetes mellitus (Type 1) is 2.88%. Among clinical features at presentation, 56.5% presented with polyuria, 34.8% with polydipsia, 21.7% with polyphagia, 39.1% with weight loss. 26.1% of patients had diabetic ketoacidosis at presentation. The majority of children have deranged HbA1C levels (94.4%). It is concluded that children presented with higher HbA1c levels at onset and higher duration of symptoms are at greater risk for the development of complications.

Keywords: Diabetic ketoacidosis, HbA1C levels, lipodystrophies, type 1 DM

Introduction

Diabetes in children includes various causes of diabetes ranging from genetic basis, environmental, drugs or chemical induced, and infections. Still, all lead to loss of β-cell mass and functions, leading to impairment of effective glucose utilization.¹⁻⁴ Incidence is continuously increasing worldwide, almost making it an endemic disease soon. The prevalence of diabetes is rising in India; as per International Diabetes Federation (IDF 2016), an increase of over 10 million was seen from the year 2011 to 2016, counting it to about 62 million. As per the latest update from IDF 2020, among all diabetic patients, 10% constitute type 1 diabetes mellitus. The most frequent type of diabetes seen in children is type 1 diabetes mellitus. Type 1 DM is characterized by low or absent endogenous insulin levels and by dependence on exogenous insulin to prevent complications like diabetic ketoacidosis nonketotic hyperosmolar coma. Here, we had done a clinical audit at our tertiary hospital, AIIMS, Rishikesh, along with a literature review of Type 1 DM in children.

Clinical Audit

Aims

Point prevalence of insulin-dependent diabetes mellitus (Type 1 DM) and analysis of its clinical correlates in children attending tertiary care pediatric unit, AIIMS, Rishikesh.

Objectives

To estimate point prevalence of insulin-dependent diabetes mellitus (Type 1 DM) in children (0-18 years of age) and to analyze clinical correlates of type 1 diabetes mellitus.
Materials and Methods

Study design
A retrospective study was conducted in the pediatric department of tertiary level hospital AIIMS Rishikesh. (clinical audit of children with diabetes mellitus).

Study duration
From April 2015 to September 2017, i.e., two years six months

Inclusion and exclusion criteria
From April 2015 to September 2017, i.e., 2 years 6 months, all the children admitted with diabetes were enrolled.

Methodology: We found 23 patients who are admitted with the diagnosis of type 1 DM. Their clinical features, including symptoms & signs, biochemical parameters, complications & treatment modalities, were documented in a computerized datasheet. Since, this is a retrospective audit so exempted from ethical approval as per institute policy.

Statistical analysis
All the data were analyzed using Epi info software. The prevalence of Type 1 DM among admitted patients during the period was calculated. Percentages of clinical features at admission were analyzed by calculating percentages.

Results
Prevalence of diabetes mellitus (Type 1) is 2.88%. 9/23 (39.1%) female and 14/23 (60.9%) male with Type 1 DM [Figure 1]. 56.5% presented with polyuria, 34.8% with polydipsia, 21.7% with polyphagia, 39.1% with weight loss [Figure 2]. 26.1% of patients had diabetic ketoacidosis at presentation. 17.4% of patients had UTI as an associated complication. 17 patients out of 18 patients had deranged HbA1C levels, which is 94.4%. 3 out of 23 patients had a positive family history, two patients had a father with type 2 DM, and another had a positive history in both grandparents (paternal & maternal) of type 2 DM. 2 patients (10.5%) had poor compliance to management. 3 patients (13%) had lipodystrophies, Diabetic retinopathy in 4.3% & subcapsular cataract in 4.3%.

Discussion
Type 1 DM: characterized by low/absent endogenous insulin & dependence on exogenous insulin to prevent complications like DKA & NKHC. Menon et al[5] had estimated the prevalence of type 1 DM <1-3.6%, which is similar to the prevalence of Type 1 DM of 2.88% in our study. Karnataka state T1DM registry estimated that prevalence among boys was 3.7/100000 & girls was 4/100000 over 13 years, whereas in our study, 60.9% boys & 39.1% girls were affected. Kumar et al. had reported poor glycemic control in 10.7% of 39 (1040) patients only, whereas in our study HbA1c was deranged in 94.4% of patients, which is higher than Kumar et al[6]. This can be explained as being it a tertiary care hospital only severe cases had been referred here, or there may be poor awareness about diabetes and its treatment in hilly areas here. Majaliwa et al. found in their study that 75% of children presented with diabetic ketoacidosis (DKA) at admission, which is higher than our study, which is 26.6%. In our study, we have found complications like lipodystrophy in 13%, diabetic retinopathy in 4.3% & subcapsular cataract in 4.3% which is lower than Kumar et al[6] who reported complications like retinopathy in 8.4% (14/166), neuropathy 5.2% (12/230), nephropathy 8.6% (20/230), hypertension 2.6% (6/230). This can be due to earlier reporting to our center for diagnosis at the onset of symptoms, so that time lag for the development of long-term complications was not there. Ahmed et al[8] have also reported long-term complications in type 1 DM like diabetic retinopathy in 33% of patients; he further found that these patients were those with longer diabetes duration (p = 0.02) and higher HbA1c levels. (p = 0.009).

Conclusion
The incidence of DM is 2.88%. The most common clinical feature was polyuria. 1/4th presented with diabetic ketoacidosis as the initial presentation. There was 3% who have a positive family history. The majority of children have deranged HbA1C levels. Diabetic retinopathy is found in 4.3% of patients, which can be prevented with early diagnosis and euglycemic management.
Review of Literature

Type 1 diabetes mellitus

INTRODUCTION: Type 1 Diabetes in children, also known as insulin-dependent diabetes mellitus earlier, has in common reduced or complete absence of insulin production due to autoimmune destruction of islet cells of the pancreas. The age of presentation is usually 6 to 16 years, with the recent change in the shift towards the younger population. Patient with type 1 DM needs lifelong insulin therapy for normal survival without developing any complications of diabetes. There are four phases of diabetes: pre-diabetes, diabetes, honeymoon period, and complicated diabetes. In the pre-diabetes phase, there is a persistent decline in insulin release due to β-cell destruction by auto-antibodies.[1] During this period, autoantibody to β-cell antigens like insulin autoantibody (IAA), islet cell cytoplasm (ICA), antibodies to glutamic acid decarboxylase, and ICA512 are present in diabetic children. It is the pre-symptomatic phase that is seen after some insult in the background, due to which, after some time patient will start manifesting symptoms of diabetes.[2] In the diabetes phase, symptoms may range from polyuria, polydipsia, polyphagia, weight loss, or weight gain. If the child is missed for diagnosis in this period, the child may progress to a transient remission period known as the honeymoon period. There is some release of insulin from the residual β-cell of the pancreas in the transient remission period. In the last phase child usually presents with signs/symptoms of DM and its complications, acute or long-term complications.

ETIOLOGY: The etiology of type 1 diabetes is broadly divided into immune-mediated and idiopathic. Major histocompatibility complex (MHC) is a large region of genes that regulates the immune function of the body. It is subcategorized into human leukocyte antigen (HLA) classes I, II, III, and IV genes. Around 50% of genetic variations in these MHC regions risk the development of type 1 diabetes.[3,4] One major region associated is the binding of HLA proteins to peptides of antigens and their presentation to T-cells.[5,6] Among these, HLA class II is linked most with the susceptibility to develop the disease. Whereas HLA I is associated with earlier onset of disease in a patient with type 1 diabetes. There is also positive family history in approximately 5% of patients with diabetes. It has been found the risk of developing the disease in a child is more if the father has diabetes as compared to the mother with diabetes.[7] However, most children with type 1 DM do not have a positive history in their families, which points to some novice mutation or insult for the development of DM. Additional stress towards environmental factors leading to the development of type 1 DM has also been postulated. It has been seen that certain viral infections, mumps, and some enteroviruses lead to β-cell autoimmunity leading to the destruction of the pancreas. Diet and stress play their role in pathogenesis, but there is a lack of evidence to prove the mechanism.

PATHOGENESIS: When a patient with vulnerable genetic material is exposed to precipitating factors for diabetes mellitus, which then trigger the pathogenesis for DM to be initiated. First, there is the formation of auto-antibodies to pancreatic β-cells, which leads to the destruction of β-cells. As the destruction of β-cells ensues, the synthesis of insulin compromises.[8] It is postulated that 80% of the destruction of β-cells occurs before the disease manifests clinically. At the onset of clinical signs or symptoms, some viable β-cells may take over the function and secrets insulin, so there is a transient honeymoon period. But as it progresses further, the patient will manifest the disease or may later end up in complications due to DM. It has to be stressed here that in spite of the initial phase of autoimmune destruction of the pancreas, all patients don’t manifest overt clinical DM. Besides, as the presence of a number of autoantibodies involved in the development of DM increases, there is a rapid progression of the disease process.[9,10] Firstly, Insulin autoantibody (IAA) is formed, followed by glutamic acid decarboxylase 65 kDa, tyrosine phosphatase insulinoma–associated two, and zinc transporter eight later.[11,12] It has to be stressed that how the course of the disease will progress is also based on individualization.[13,14,15] Therefore, neither the pathogenesis nor the treatment should be based on “one for all.”[16] CLINICAL MANIFESTATION: The appearance of clinical signs and symptoms occurred in the second phase of diabetes when insulin level decreased to moderate levels due to a progressive decrease in β-cells of the pancreas. Before this phase, although the process of destruction is taking place, the child won’t show any symptoms. At this moderate decrease of insulin levels ensues catabolic state, only after feeding, leading to a reduction in peripheral glucose utilization by muscle and fat tissues resulting in postprandial hyperglycemia. As the disease progresses further to lower levels of serum insulin, it increases glycojenolysis and gluconeogenesis in the liver, resulting in even fasting hyperglycemia in the child. As the renal threshold of glycosuria exceeds, osmotic diuresis starts, and the child will develop polyuria. Further, the child develops nocturia and more intense polydipsia as chronic hyperglycemia supervenes. There is a loss of glucose (calories) in urine that results in starvation and the development of polyphagia in the child. Even though polyphagia does not cope with the amount of loss of calories in urine, the child presents with weight loss due to loss of fatty tissue.[17] These all pathological events lead to an increase in levels of stress hormones. These contra-regulatory hormones are epinephrine, growth hormone, cortisol, and glucagon. In diabetes, these hormones cause metabolic compensation, the ensuing increase in free fatty-acids production. Due to insulin deficiency and glucagon excess, the formation of ketone bodies (β-hydroxybutyrate & acetoacetate) from these free fatty acids occurs in DM, the rate of ketone body formation exceeds their peripheral utilization and renal excretion leading to ketoacidosis, manifesting as fruity breath odour. The accumulation of ketoacidosis lands the child into diabetic ketoacidosis.[18] At this moment child develops abdominal pain, nausea, and vomiting, Kussmaul respiration as the disease progresses. Compensatory rapid, deep breathing in
an attempt to excrete excess carbon dioxide results in Kussmaul respiration. As the condition worsens, the child develops a decline in neurocognitive function and coma. Although seen less frequently in children, nonketotic hyperosmolar coma can be one of the presentations, inpatient, with DM. Presenting with severe dehydration, nonketotic acidosis, Kussmaul respiration may or may not ketosis, seizures, or various neurological sign and symptoms.

**DIAGNOSIS:** Diagnostic criteria for diabetes mellitus: if any child presenting with signs and symptoms and has random blood sugar levels either 200 mg/dl or more is diagnosed as DM, or the child may present with fasting blood sugar of more than or equal to 126 mg/dl or postprandial levels (2 hours post-feeding) more than or equal to 200 mg/dl or glycated hemoglobin levels more than or equal to 6.5%.\[16\]

Additional testing for diabetes: ABG (acid-base gas analysis), serum electrolytes, urine for ketones, serum osmolality are the tests that should be done in case of a child presenting with DKA or nonketotic hyperosmolar coma.\[16\] Serum blood glucose levels more than 200 mg/dl, presence of ketonuria with blood pH <7.35, and pCO2 levels below 20 mEq/L points towards DKA. The presence of severe hypernatremia in patients with DKA suggests severe DKA. Nonketotic hyperosmolar coma can be diagnosed by blood glucose levels >800 mg/dl, may or may be mild ketosis and acidosis.

**Autoantibodies for diagnosis of immune-mediated diabetes-like islet cell autoantibodies and autoantibodies to insulin, GAD (GAD65), the tyrosine phosphatases IA-2 and IA-2b, and ZnT8 should be considered in all cases of type 1 diabetes.**\[16\] Various studies have even shown that these autoantibodies also have a role in screening at-risk populations for the development of Type 1 DM, especially if a first-degree relative has diabetes.\[21\] So, this can help to implement nutrition education and disease education to patients, thus having a role in primordial prevention. It can also help us in early diagnosis and prevention from complications if the child can be followed closely.\[22\]

Testing for associated auto-immunities: In children, diabetes is associated with many other autoimmune diseases, so additional testing to rule out the same should also be done.\[16\]  
- Tissue transglutaminase & IgA levels: Coeliac disease
- Thyroid profile: Hypothyroidism
- Anti-thyroglobulin antibodies & anti-thyroid peroxidase: Thyroiditis.

If done timely, management of these autoimmune diseases in all cases of diabetes mellitus, can improve the overall prognosis.

**COMPLICATIONS:** The degree and duration of hyperglycemia much influence the development of complications. So, early diagnosis, intensive management of hyperglycemia, and prevention of hypoglycaemic episodes can reduce diabetes complications.\[23\] All primary care should be motivated to do random blood sugar estimation of children coming with symptoms suggestive of early stage of the disease like, polyuria, polydipsia or sudden change in weight. Diabetic children should be managed in a way to reduce both hyperglycaemic and hypoglycaemic fluctuation, if the need arise should be referred aptly.

Due to insulin therapy: Psychological or behavioral problems due to self-testing or injections, lipodystrophy at the injection site, hypoglycaemic attacks.

Long-term complications: Microvascular complications include retinopathy or nephropathy. Macrovascular complications include cerebrovascular diseases, coronary artery disease, and peripheral vascular diseases. Peripheral and autonomic neuropathies can also be seen. It has been found in many studies that the longer the duration of symptoms with poorly controlled diabetes, there is a high risk of developing complications.\[7,24-28\] [Table 1]

**Conclusion:** There is a rising burden of type 1 DM worldwide, which is further increasing due to lifestyle modifications. Early identification of symptoms, timely screening, and maintaining euglycemia should be prime to reduce the prevalence of complications due to diabetes.

**Key points**

- Routine screening by random blood sugar levels of all children with early symptoms like polyuria can help in early diagnosis.
- Auto-antibodies testing causing DM, in children with first degree of relatives suffering from diabetes, and lifestyle modifications can help in primordial prevention.
- Controlling the duration of hyperglycaemic as well as hypoglycaemic phase in patients can help to delay the development of long-term complications.

**Financial support and sponsorship**
Nil.

| Table 1: Percentages of complications reported in various research articles of type 1 Diabetes Mellitus |
|-------------------------------------------------------------------------------------------------|
| **Long term complications** | **Research article** | **Percentages** |
| Diabetic retinopathy | Nordwall et al\[24\] | 27 |
|                      | Majaliwa et al\[7\] | 22.7 |
|                      | Mayer-Davis et al\[29\] | 17 |
|                      | Salardi et al\[30\] | 56.2 |
|                      | Ramachandran et al\[27\] | 13.4 |
| Nephropathy | Nordwall et al\[24\] | 5 |
|                      | Demirel et al\[31\] | 16.1 |
|                      | Ramachandran et al\[27\] | 7.1 |
| Neuropathy | Nordwall et al\[24\] | 59 |
|                      | Demirel et al\[31\] | 0.6 |
|                      | Ramachandran et al\[27\] | 3 |
| Coronary artery disease | Demirel et al\[31\] | 12.3 |
|                      | Ramachandran et al\[27\] | 1 |
Conflicts of interest

There are no conflicts of interest.

References

1. Skyler JS, Bakris GL, Bonifacio E, Darrow T, Eckel RH, Groop L, et al. Differentiation of diabetes by pathophysiology, natural history, and prognosis. Diabetes 2017;66:241-55.
2. Matveyenko AV, Butler PC. Relationship between beta-cell mass and diabetes onset. Diabetes Obes Metab 2008;10(Suppl. 4):23-31.
3. Campbell-Thompson M, Fu A, Kaddis JS, Wasserfall C, Schatz DA, Pugliese A, et al. Insulitis and b-cell mass in the natural history of type 1 diabetes. Diabetes 2016;65:719-31.
4. Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA. b-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: A new analysis. J Clin Endocrinol Metab 2005;90:493-500.
5. Menon P, Viramani A, Shah P, Raju R, Sethi A, Sethia S, et al. Childhood onset diabetes mellitus in India: An overview. Int J Diabetes Dev Ctries 1990;10:1-6.
6. Kumar P, Krishna P, Reddy SC, Gurappa M, Aravind SR, Munichoodappa C. Incidence of type 1 DM & associated complications among children & young adults: Result from Karnataka diabetic Registery (1995-2008). J Indian Med Assoc 2008;106:708-11.
7. Majaliwa ES, Munuhhi E, Ramaiya K, Mpembeni R, Sanyiwa A, Mohn A, Chiarelli F. Survey on acute and chronic complications in children and adolescents with type 1 diabetes at Muhimbili National Hospital in Dar es Salaam, Tanzania. Diabetes Care 2007;30:1827-92.
8. Ahmed H, Elshaikh T, Abdullah M. Early diabetic nephropathy and retinopathy in patients with type 1 diabetes mellitus attending Sudan Childhood Diabetes Centre. J Diabetes Res 2020;2020:7181383. doi: 10.1155/2020/7181383.
9. Noble JA, Valdes AM, Varney MD, Carlson JA, Moonsamy P, Fear AL, et al. HLA class I and genetic susceptibility to type 1 diabetes: Results from the type 1 diabetes genetics consortium. Diabetes 2010;59:2972-9.
10. Hu X, Deutsch AJ, Lenz TL, Onengut-Gumuscu S, Han R, Chen WM, et al. Additive and interaction effects at three amino acid positions in HLA-DQ and HLA-DR molecules drive type 1 diabetes risk. Nat Genet 2015;47:898-905.
11. Hämäläinen A-M, Knip M. Autoimmunity and familial risk of type 1 diabetes. Curr Diab Rep 2002;2:347-53.
12. Ziegler AG, Rewers M, Simell O, Simell T, Lempainen J, Steck A, et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA 2013;309:2473-9.
13. Steck AK, Vehik K, Bonifacio E, Lernmark A, Ziegler AG, Hagopian WA, et al. Predictors of progression from the appearance of islet autoantibodies to early childhood diabetes: The environmental determinants of diabetes in the young (TEDDY). Diabetes Care 2015;38:808-13.
14. Orban T, Sosenko JM, Cuthbertson D, Krischer JP, Skysler JS, Jackson R, et al. Pancreatic islet autoantibodies as predictors of type 1 diabetes in the diabetes prevention trial-type 1. Diabetes Care 2009;32:2269-74.
15. Bonifacio E. Predicting type 1 diabetes using biomarkers. Diabetes Care 2015;38:899-96.
16. American Diabetes Association. Classification and diagnosis of diabetes. Standard of Medical Care in Diabetes. Diabetes Care 2016;39:S13-22.
17. Insel RA, Dunne J-L, Atkinson MA, Chiang J-L, Dabelea D, Gottlieb PA, et al. Staging pre-symptomatic type 1 diabetes: A scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care 2015;38:1964-74.
18. Insel R, Dutta S, Hedrick J. Type 1 diabetes: Disease stratification. Biomed Hub 2017;2:1-16.
19. Akil AA, Yassin E, Al-Maraghi A, Aliyev E, Al-Malki K, Fakhar KA. Diagnosis and treatment of type 1 diabetes at the dawn of the personalized medicine era. J Transl Med 2021;19:137.
20. Kahanovitz L, Sluss PM, Russell SJ. Type 1 diabetes-A clinical perspective. Point Care 2017;16:37-40.
21. Insel RA, Dunne J-L, Atkinson MA, Chiang J-L, Dabelea D, Gottlieb PA, et al. Staging pre-symptomatic type 1 diabetes: A scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care 2015;38:1964-74.
22. Sosenko JM, Skysler JS, DiMeglio LA, Beam CA, Krischer JP, Greenbaum CJ, et al. A new approach for diagnosing type 1 diabetes in autoantibody-positive individuals based on prediction and natural history. Diabetes Care 2015;38:271-6.
23. The Diabetes Control and Complications Trial Research Group, Nathan DM, Gough S, Lachin J, Clevy P, Crofford O, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
24. Nordwall M, Hyllnermark L, Ludvigsson J. Early diabetic complications in a population of young patients with type 1 diabetes mellitus despite intensive treatment. J Pediatr Endocrinol Metab 2006;19:45-54.
25. Mayer-Davis EJ, Davis C, Saadine J, D’Agostino RB, Dabelea D, Dolan L, et al. Diabetic retinopathy in the SEARCH for Diabetes in Youth Cohort: A pilot study. Diabet Med 2012;29:1148-52.
26. Salardi S, Porta M, Maltoni G, Rubbi F, Rovere S, Cerutti F, et al. Infant and toddler type 1 diabetes: Complications after 20 years’ duration. Diabetes Care 2012;35:829-33.
27. Ramachandran A, Snehalatha C, Sasikala R, Sathyavani K, Vijay V. Vascular complications in young Indian patients with type 1 diabetes mellitus. Diabetes Res Clin Pract 2000;48:31-6.
28. Demirel F, Tepe D, Kara O, Esen I. Microvascular complications in adolescents with type 1 diabetes mellitus. J Clin Res Pediatr Endocrinol 2013;5:145-9.